Specific Augmentation of Plantar Skin Blood Flow by Lipo-PGE1 Assessed in Tetrodotoxin- and NG-Nitro-L-Arginine-Treated Rats
- 1 April 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 35 (4) , 630-637
- https://doi.org/10.1097/00005344-200004000-00017
Abstract
1Vasodilating effects of prostaglandin E1 incorporated in lipid microspheres (lipo-PGE1) were compared with those of prostaglandin E1 (PGE1) or its cyclodextrin clathrated preparation (PGE1-CD) on plantar skin blood flow in rats treated with tetrodotoxin and N(G)-nitro-L-arginine (L-NNA). Tetrodotoxin (50 microg/kg, i.v.) could totally inhibit the pressor response to electrical stimulation of the spinal cord, and the reflex tachycardia due to the depressor response to acetylcholine. Furthermore, L-NNA (30 mg/kg, i.v.) was used to counteract the lowering of the systemic blood pressure and peripheral vascular tone by elimination of sympathetic nerve activity, and to maintain the arterial blood pressure at the control level. Lipo-PGE1 increased plantar skin blood flow 4 to 6 times more potently than PGE1-CD or PGE1 in the treated rats. Furthermore, lipo-PGE1 increased plantar skin blood flow about 3 times more selectively than PGE1-CD. We also assessed several vasodilators, including terbutaline, nitroprusside, nicardipine, and papaverine in tetrodotoxin- and L-NNA-treated rats. However, none of them could selectively increase plantar blood flow despite the prominent depressor responses achieved. These results suggest that PGE1 preparations, especially lipo-PGE1 could potently and selectively increase plantar skin blood flow in rats treated with tetrodotoxin and L-NNA.Keywords
This publication has 30 references indexed in Scilit:
- Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesionsProstaglandins, Leukotrienes & Essential Fatty Acids, 1990
- Prostaglandin E1: A reviewProstaglandins, Leukotrienes & Essential Fatty Acids, 1988
- Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in manJournal of Pharmacy and Pharmacology, 1983
- Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.Annals of the Rheumatic Diseases, 1981
- Treatment of vasospastic disease with prostaglandin E1.BMJ, 1980
- INTRAVENOUS PROSTAGLANDIN E1 IN SEVERE PERIPHERAL VASCULAR DISEASEThe Lancet, 1976
- Inactivation of Prostaglandins by the LungsNature, 1970
- Prostaglandins A1, A2 and 19‐hydroxy A1; their actions on smooth muscle and their inactivation on passage through the pulmonary and hepatic portal vascular bedsBritish Journal of Pharmacology, 1969
- CLINICAL AND METABOLIC EFFECTS OF DIFFERENT DOSES OF PROSTAGLANDIN E1 IN MANActa Medica Scandinavica, 1968
- Prostaglandins: Their Disappearance from and Release into the CirculationNature, 1967